SecBot SecBot
8-K ·Filed Nov 9, 2026

CRMD

CorMedix Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed7d 19h ago SEC0001213900-26-117213
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

Monitor the integration of the four Heron products and their revenue contribution in upcoming quarters. The loan's amortization schedule and potential adjustment trigger (TTM Net Rezzayo Revenues >= $95M by Sep 2029) will be key credit metrics to track.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

CRMD drug pipeline →

rezafungin

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
Next catalyst
NDA filing · 2026

What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$5.47
T+0 close · Nov 9, 2026 · via day close
Latest settled
−11.88%
T+5 · $4.82
Vs SPY
−10.19%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $5.47entry
  2. T+1 · 7d ago −1.83%α −1.46% · $5.37
  3. T+5 · 20h ago −11.88%α −10.19% · $4.82
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix entered into a loan agreement with BioPharma Credit for up to $50M in term loans to fund the acquisition of four commercial-stage products (Cinvanti, Zynrelef, Aponvie, Sustol) from Heron Therapeutics. The transaction includes a $145M cash component plus 14.58M shares of CorMedix common stock, with the loan secured by substantially all assets. The combined financing and acquisition significantly increases CorMedix's leverage and adds four marketed products to its portfolio.

Key Financial Metrics

Deal Value
$204.0M
Deal Type
acquisition
Offering Size
$50.0M

Key Facts

  • Loan agreement for up to $50M in term loans (Tranche A and Tranche B) from BioPharma Credit lenders
  • Proceeds used to fund acquisition of Heron Therapeutics products: Cinvanti, Zynrelef, Aponvie, Sustol
  • Asset purchase agreement with Heron: $145M base cash consideration plus 14,583,333 shares of CorMedix common stock
  • Loan interest rate is Term SOFR plus 5.75% per annum, with quarterly payments starting ~3 years after closing
  • Loan matures on Term Loan Maturity Date, with optional prepayment subject to make-whole and prepayment premium
  • Loan secured by substantially all assets of CorMedix and its subsidiaries
  • Heron acquisition also includes potential royalty and earn-out payments on net sales of acquired products
  • CorMedix market cap is $407M; loan size represents ~12.3% of market cap

Financial Impact

Up to $50M in new debt financing; $145M cash plus 14.58M shares (~$59M at $4.05/share) in acquisition consideration; total deal value approximately $204M plus potential royalties

debtdilutionrevenue

Risk Factors

  • Increased leverage with up to $50M in secured debt
  • Integration risk from acquiring multiple commercial-stage products from Heron
  • Potential dilution from 14.58M shares issued to Heron (approximately 26% of current shares outstanding based on $407M market cap)
  • Loan contains prepayment penalties and make-whole provisions that increase cost of early refinancing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-117213
Document: ea031142301ex2-1.htm0001213900-26-117213

Track record

21 reports on CRMD

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
  2. Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  3. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  4. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 6/10 Viewing Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  6. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  7. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
  9. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
  10. Aug 13, 202613w ago 8-K Neutral 5/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026